[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-401451-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-401451-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","hiv-pre-exposure-prophylaxis-prep-updates-raja-iskandar-raja-azwa","HIV Pre-exposure Prophylaxis (PrEP) Updates - Raja Iskandar Raja Azwa","","This slide deck summarizes recent updates on HIV pre-exposure prophylaxis (PrEP), grounded mainly in WHO guidance and oral TDF/FTC PrEP. It covers de-medicalization of PrEP, practical timelines for starting and stopping, on-demand PrEP concepts, and how HIV ST and PrEP intersect. It outlines differentiated service delivery approaches, highlights LA cabotegravir, and discusses PrEP initiation across multiple Asia-Pacific countries. The materials also review eligibility updates (2021), HIV self-testing, viral hepatitis testing, kidney function monitoring, and evidence on creatinine screening and adverse kidney outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/hiv-pre-exposure-prophylaxis-prep-updates-raja-iskandar-raja-azwa/401451/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/hiv-pre-exposure-prophylaxis-prep-updates-raja-iskandar-raja-azwa/401451.png","ImageObject",300,407,{"name":42,"@type":43},"Bulrr","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-27",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What topics are covered in the PrEP updates talk?","Question",{"text":63,"@type":64},"The outline includes de-medicalization, starting/stopping timelines, on-demand PrEP, HIV ST and PrEP, differentiated service delivery, and LA cabotegravir.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is PrEP eligibility described in the 2021 updated guidance?",{"text":68,"@type":64},"Eligibility is framed using risk-based identification for all sexually active adults and adolescents with factors such as an HIV-positive partner not virally suppressed, recent bacterial STIs, inconsistent/no condom use, and universal PrEP education.",{"name":70,"@type":61,"acceptedAnswer":71},"Why focus on creatinine monitoring and kidney function screening?",{"text":72,"@type":64},"The deck summarizes trial evidence showing increased kidney adverse events with PrEP and concludes that screening and monitoring should prioritize older individuals, those with baseline creatinine clearance under 90 mL/min, and those with kidney-related comorbidities.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},401451,1790673021,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},5909892115043,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","HIV Pre-exposure Prophylaxis  \n(PrEP) Updates  \nRaja Iskandar Raja Azwa  \nInfectious Diseases Unit, Faculty of Medicine  \nUniversity Malaya  \nOutline of my talk  \n• De-medicalization of PrEP  \n• Starting and stopping PrEP timelines  \n• On demand PrEP  \n• HIV ST and PrEP  \n• Differentiated service delivery approaches  \n• LA Cabotegravir  \n✽ Mainly limiting to WHO Guidelines and oral TDF/FTC PrEP  \nPrEP initiation in the Asia-Pacific, March 2022  \nCountry  \nAustralia Thailand Vietnam Nepal Taiwan Philippines Myanmar India  \nCumulative Initiations Across All Products  \n49,355  \n41,027  \n33,938  \n4,410  \n4,142  \n3,192  \n1,779  \n1,651  \nStudy procedures,  \nMy PrEP Demonstration Project  \n\n| Procedure |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| Rapid HIV Ag/Ab |  |  |  | HIV risk and i | ncidence matters – |  |  |  |  |\n| HIV POC VL |  |  |  | screening tool\u003Cbr>What about o | s?\u003Cbr>ther gaps – STIs, unme | t |  |  |  |\n| Creatinine |  |  |  | contraceptive\u003Cbr>Positivity rate | need, IPV, others  at screening – linkage |  |  |  |  |\n| Rectal CT/NG |  |  |  | to ART |  |  |  |  |  |\n| RPR/TPHA |  |  |  |  |  |  |  |  |  |\n| HBsAg/Ab |  |  |  |  |  |  |  |  |  |\n| HCV-Ab |  |  |  |  |  |  |  |  |  |\n| Questionnaire |  |  |  |  |  |  |  |  |  |\n| Diary (weekly) |  |  |  |  |  |  |  |  |  |\n|  |  |  |  | C |  |  |  |  |  |\n| Drug dispensing | |  |  | on | ext |  |  | |  |\n|  |  |  |  |  |  |  |  |  |  |\n|  |  |  |  | Safety | impact |  |  |  |  |\n| Pill count\u003Cbr>R | \u003Cbr>achel Baggaley | Global HIV, Hepatitis an |  |  |  |  |  |  | | 4 |\n|  |  | d STIs Programmes | World Health Organization |  |  |  |  |  |  |  |\n\nt &  \n4  \nMaking PrEP more effective and efficient:  \nbalancing costs, efficiency and impact  \n‘Ideal package’  \nHIV testing  \nPrEP pills  \nCreatinine  \nHep B / C Basic services STI-lab based HIV testing PEP PrEP pills Contraception“Effective use” support And more…  \nCondoms and lube  \nDemedicalization & Simplifying PrEP service delivery  \nNew PrEP Guidance:  \n• Kidney function monitoring  \n• HIV self testing (HIVST) for PrEP  \n• Viral hepatitis testing  \n• Starting and stopping PrEP  \n• Differentiated service delivery approaches  \nPeople’s lives and PrEP journeys are more complicated in reality  \nlong break  \nStarting PrEP  \nHIV+ diagnosis link to care  \nMisses some doses or splits pills  \n7  \nRisk period changes and stops PrEP for season  \nRisk period changes again Re-start PrEP  \nHeather Marie Schmidt, 3rd National PrEP Consultation. Feb 2022  \nCDC PrEP Clinical Practice Guidelines  \nPrEP Eligibility (Updated 2021)  \n Risk based identification   \nAll sexually active adults & adolescents  \nSO WHAT’S NEW?  \nHIV risk (Anal or vaginal sex ) in the past 6 months  \n• HIV positive partner (not virally suppressed)  \n• Bacterial STI in the past 6 months  \n• History of inconsistent or no condom use  \n• Universal PrEP Education:  \nRecommendation to inform all sexually active adults and adolescents about PrEP  \n•  Offer Prep To Anyone Asking For PrEP  \nAsking for PrEP = Anticipated risk of  \nacquiring HIV  \n[https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf](https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf)  \nSexual History Taking: Language matters  \n• Taking “risk” out of the equation  \nSexual history: Requires asking  \n• Use positive ”gain-framing” messages focusing on empowerment & health promotion  \n• Open ended questions about sexual behaviours  \nSexual Health Based  \n“PrEP is a tool that can be used to reduce anxiety about HIV and take control of your sexual health.”  \nVS  \nRisk Based  \n“PrEP is for people at high risk for HIV who want to decrease their risk of becoming infected  \n• 11 RCTs, 13523 participants  \n• PrEP use was associated with increased risk of grade 1 and higher kidney adverse events (pooled OR1∙49, 95% CI 1∙22–1∙81) and grade 2 and higher events (OR 1∙75, 0∙68–4∙49)  \n• 349 (2∙43%)/14368 PrEP users with longtitudinal analys","cbCaidFkFMxntldo","https://ap.wps.com/l/cbCaidFkFMxntldo","pdf",6450511,33,"English","# Outline of my talk\n## De-medicalization of PrEP\n## Starting and stopping PrEP timelines\n## On demand PrEP\n## HIV ST and PrEP\n## Differentiated service delivery approaches\n## LA Cabotegravir\n# PrEP initiation and service procedures\n## PrEP initiation in Asia-Pacific (March 2022)\n## Study procedures and screening tools\n## Making PrEP more effective and efficient\n# PrEP guidance and clinical recommendations\n## PrEP Eligibility (Updated 2021)\n## HIV testing and risk-based vs sexual-history approaches\n## Kidney function screening and monitoring evidence\n# New WHO guidance referenced","[{\"question\":\"What topics are covered in the PrEP updates talk?\",\"answer\":\"The outline includes de-medicalization, starting/stopping timelines, on-demand PrEP, HIV ST and PrEP, differentiated service delivery, and LA cabotegravir.\"},{\"question\":\"How is PrEP eligibility described in the 2021 updated guidance?\",\"answer\":\"Eligibility is framed using risk-based identification for all sexually active adults and adolescents with factors such as an HIV-positive partner not virally suppressed, recent bacterial STIs, inconsistent/no condom use, and universal PrEP education.\"},{\"question\":\"Why focus on creatinine monitoring and kidney function screening?\",\"answer\":\"The deck summarizes trial evidence showing increased kidney adverse events with PrEP and concludes that screening and monitoring should prioritize older individuals, those with baseline creatinine clearance under 90 mL/min, and those with kidney-related comorbidities.\"}]","HIV Pre-exposure Prophylaxis (PrEP) Updates - Raja Iskandar Raja Azwa | PDF",1790520045,83]